The kidneys are the body's main purification plant, filtering wastes and excess fluids from the blood. Historically, the last stage of kidney failure inevitably resulted in death. In the 1940's the first functioning dialysis machine made it possible to survive despite almost non-existent renal function. Today, people with kidney failure can live thanks to treatments such as dialysis and kidney transplant.

‍

Approximately four million people worldwide suffer from end-stage renal disease (ESRD), which is an increasingly prevalent healthcare problem caused primarily by diabetes and high blood pressure.

‍

Triomed exists and works to help ESRD patients to a better life. The company, located in the Ideon Science Park in Lund, has invested ten years developing a wearable therapy system for continuous dialysis treatment for patients with kidney failure. Triomed has become specialists in portable dialysis solutions and heart failure treatments.

‍

There are two sorts of dialysis. In hemodialysis the patient is treated at a hospital 3-4 times a week, often for several hours per occasion. Peritoneal dialysis (PD) is less intrusive, allowing the patient to keep up his or her everyday activities such as working, studying, watching TV, cooking or putting the kids to bed. The kidneys are cleaned while the patient can do something else - even sleeping.

PD is a home therapy preferred by both patients and payers. For the patient the therapy has less lifestyle impact. It is also a much cheaper form of dialysis. The global cost of dialysis treatment is estimated at approximately $85 billion.

‍

Triomed’s vision is to develop wearable systems that ensure that PD remains the preferred dialysis alternative both for patients and health care providers. Supported by world leading medical experts and engineers, Triomed's revolutionary wearable therapy system called Carry Life is effective, simple, safe, ergonomic and economic. There are several competitors striving to develop flexible and portable dialysis solutions that allow patients a better life. Triomed's successful product development is gaining attention in the international research community and its first patient studies showed positive results.

‍

Patrick Greatrex, CEO of Triomed, interprets the interest in the company in part as an expression of the industry's need for innovation.

"What we do is very innovative and interest is growing rapidly. It encourages us to continue building clinical evidence and take our ideas and solutions beyond the research lab. In the short term, we are working to prove that our treatments can help both patients and healthcare providers, with the ultimate goal of providing products that will improve the lives of millions of people."

‍

‍

‍

‍